MedTrace Logo

Qualitative Evaluation of Tear Fluid and Blood for Auto Antibodies Produced in Response to COVID-19

NCT04542980 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 44

Last updated 2022-03-21

No results posted yet for this study

Summary

This study objective is to collect tear and blood samples from individuals with positive SARS-COV2 diagnosis and test those samples for the presence of various SARS-COV2 viral antigens and autoantibodies.

Conditions

  • SARS-CoV 2 Infection
  • Covid19

Interventions

DIAGNOSTIC_TEST

SARS-CoV2 Autoantibody detection

Through the data collected from this study we hope to support the development of an ELISA assay for the detection of IgM and IgG autoantibodies produced in response to the presence of SARS-CoV2

Sponsors & Collaborators

  • Namida Lab

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-15
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04542980 on ClinicalTrials.gov